Generic ProAir RespiClick Availability
Last updated on Nov 6, 2024.
See also: Generic ProAir HFA
ProAir RespiClick is a brand name of albuterol, approved by the FDA in the following formulation(s):
PROAIR RESPICLICK (albuterol sulfate - powder, metered;inhalation)
-
Manufacturer: TEVA BRANDED PHARM
Approval date: March 31, 2015
Strength(s): EQ 0.09MG BASE/INH [RLD]
Has a generic version of ProAir RespiClick been approved?
No. There is currently no therapeutically equivalent version of ProAir RespiClick available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of ProAir RespiClick. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Dose counters for inhalers, inhalers and methods of assembly thereof
Patent 10,022,510
Issued: July 17, 2018
Inventor(s): Walsh Declan & Fenlon Derek & Kaar Simon & Hazenberg Jan Geert & Buck Daniel & Clancy Paul & Uschold Robert Charles & Karg Jeffrey A.A tape system for a dose counter for an inhaler, the tape system having a main elongate tape structure, dosing indicia located on the main elongate tape structure, tape positioning indicia located on the main elongate tape structure, a tape size marker located on the main elongate tape structure indicating a number of dosing indicia on the tape, and priming indicia located on the main elongate tape structure, the priming indicia being located between the dosing indicia and one end of the tape.
Patent expiration dates:
- May 18, 2031✓
- May 18, 2031
-
Dose counter for inhaler having an anti-reverse rotation actuator
Patent 10,124,131
Issued: November 13, 2018
Inventor(s): Walsh Declan & Fenlon Derek & Kaar Simon & Hazenberg Jan Geert & Buck Dan & Clancy Paul & Uschold Robert Charles & Karg Jeffrey A.An incremental dose counter for a metered dose inhaler having a body arranged to retain a canister for movement of the canister relative thereto, the incremental dose counter having a main body, an actuator arranged to be driven and to drive an incremental output member in a count direction in response to canister motion, the actuator being configured to restrict motion of the output member in a direction opposite to the count direction.
Patent expiration dates:
- May 18, 2031✓
- May 18, 2031
-
Dose counter for inhaler having an anti-reverse rotation actuator
Patent 10,561,808
Issued: February 18, 2020
Inventor(s): Walsh Declan & Fenlon Derek & Kaar Simon & Hazenberg Jan Geert & Buck Daniel & Clancy Paul & Uschold Robert Charles & Karg Jeffrey A.A dose counter for an inhaler includes a counter display arranged to indicate dosage information, and a drive system arranged to move the counter display incrementally in a first direction from a first station to a second station in response to actuation input. A regulator is provided which is arranged to act upon the counter display at the first station to regulate motion of the counter display at the first station to incremental movements.
Patent expiration dates:
- January 1, 2032✓
- January 1, 2032
-
Dry powder inhalation apparatus
Patent 10,765,820
Issued: September 8, 2020
Inventor(s): Barney Brian & "OLeary David" & Striebig Rachel
Assignee(s): NORTON HEALTHCARE LTD.A dry powder inhalation apparatus includes a housing, a reservoir for medicament located within the housing, a mouthpiece disposed on the housing for insertion in the mouth of a user for inhalation of a predetermined dose of medicament, a delivery channel between a discharge outlet of the reservoir and the mouthpiece for delivering the predetermined dose of medicament, a device positioned within the housing and normally held adjacent the reservoir for receiving the predetermined dose of medicament from the discharge outlet and transferring it to the delivery channel, and a release mechanism adapted to release the device and permit controlled movement thereof to the delivery channel for the delivery, the release mechanism being located at least partially outside of the housing for manual operation by the user.
Patent expiration dates:
- May 19, 2025✓
- May 19, 2025
-
Dry powder inhalation apparatus
Patent 8,651,103
Issued: February 18, 2014
Inventor(s): Barney Brian & "OLeary David" & Striebig Rachel
Assignee(s): Norton Healthcare Ltd.The invention relates to dry powder inhalation apparatus usually operable by breath of a user which provides for controlled and smooth transfer of medicament during multiple actuations by a user. A mechanism of the apparatus for achieving this controlled and smooth transfer includes a device () normally held adjacent a reservoir for receiving medicament in a cup or receptacle () and which is generally movable transversely of a longitudinal axis of the apparatus to delivery channels of the apparatus. This bodily shifting of the device () is achieved by a yoke acting on an abutment () thereof. Spillage of medicament in the apparatus is avoided.
Patent expiration dates:
- March 26, 2028✓
- March 26, 2028
-
Dose counters for inhalers, inhalers and methods of assembly thereof
Patent 8,978,966
Issued: March 17, 2015
Inventor(s): Walsh Declan & Fenlon Derek & Kaar Simon & Hazenberg Jan Geert & Buck Dan & Clancy Paul & Uschold Robert Charles & Karg Jeffrey A.A manually operated metered dose inhaler includes a dose counter chamber including a dose display tape driven by a ratchet wheel which is driven in turn by an actuator pawl actuated by movement of a canister, the tape unwinding from a stock bobbin during use of the inhaler, a rotation regulator being provided for the stock bobbin and including a wavelike engagement surface with concavities which engage against control elements in the form of protrusions on resilient forks of a split pin thereby permitting incremental unwinding of the stock bobbin yet resisting excessive rotation if the inhaler is dropped onto a hard surface.
Patent expiration dates:
- January 13, 2032✓
- January 13, 2032
-
Dose counters for inhalers, inhalers and methods of assembly thereof
Patent 9,216,260
Issued: December 22, 2015
Inventor(s): Walsh Declan & Fenlon Derek & Kaar Simon & Hazenberg Jan Geert & Buck Dan & Clancy Paul & Uschold Robert Charles & Karg Jeffrey A.A manually operated metered dose inhaler includes a dose counter chamber including a dose display tape driven by a ratchet wheel which is driven in turn by an actuator pawl actuated by movement of a canister, the tape unwinding from a stock bobbin during use of the inhaler, a rotation regulator being provided for the stock bobbin and including a wavelike engagement surface with concavities which engage against control elements in the form of protrusions on resilient forks of a split pin thereby permitting incremental unwinding of the stock bobbin yet resisting excessive rotation if the inhaler is dropped onto a hard surface.
Patent expiration dates:
- June 28, 2031✓
- June 28, 2031
-
Dry powder inhalation apparatus
Patent 9,463,288
Issued: October 11, 2016
Inventor(s): Barney Brian & "OLeary David" & Striebig Rachel
Assignee(s): NORTON HEALTHCARE LTD.A dry powder inhalation apparatus operable by breath of a user which provides for controlled and smooth transfer of medicament during multiple actuations by a user. A mechanism of the apparatus for achieving this controlled and smooth transfer includes a device normally held adjacent a reservoir for receiving medicament in a cup or receptacle and which is generally movable transversely of a longitudinal axis of the apparatus to delivery channels of the apparatus. This bodily shifting of the device is achieved by a yoke acting on an abutment thereof. Spillage of medicament in the apparatus is avoided.
Patent expiration dates:
- May 19, 2025✓
- May 19, 2025
-
Dose counter for inhaler having a bore and shaft arrangement
Patent 9,731,087
Issued: August 15, 2017
Inventor(s): Walsh Declan & Fenlon Derek & Kaar Simon & Hazenberg Jan Geert & Buck Daniel & Clancy Paul & Uschold Robert Charles & Karg Jeffrey A.A dose counter for an inhaler, the dose counter having a display tape arranged to be incrementally driven from a tape stock bobbin onto an incremental tape take-up drive shaft, the bobbin having an internal bore supported by and for rotation about a support shaft, at least one of the bore and support shaft having a protrusion which is resiliently biased into frictional engagement with the other of the bore and support shaft with longitudinally extending mutual frictional interaction.
Patent expiration dates:
- May 18, 2031✓
- May 18, 2031
More about ProAir RespiClick (albuterol)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (108)
- Latest FDA alerts (5)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: adrenergic bronchodilators
- Breastfeeding
Patient resources
Other brands
Ventolin, Ventolin HFA, ProAir HFA, Proventil, ... +5 more
Professional resources
Other brands
Ventolin, ProAir HFA, Proventil HFA, ProAir Digihaler
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.